Capecitabine therapy for refractory metastatic thyroid carcinoma: A case series

Thyroid

Volumn 16, Issue 8, 2006, Pages 801-810

  Gilliam, Lisa K ^a,b   Kohn, Aimee D ^b   Lalani, Tasneem ^b   Swanson, Paul E ^b   Vasko, Vasyl ^c   Patel, Aneeta ^c   Livingston, Robert B ^a   Pickett, Cheryl A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; DACARBAZINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXORUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; IODINE 131; LEVOTHYROXINE; OCTREOTIDE; PACLITAXEL; RADIOACTIVE IODINE; TAXANE DERIVATIVE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE INHIBITOR; THYROGLOBULIN; TUMOR MARKER;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOEMBRYONIC ANTIGEN; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; THYMIDINE PHOSPHORYLASE; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 33751052512     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.16.801     Document Type: Conference Paper

References (52)

1. Sherman SI 2003 Thyroid carcinoma. Lancet 361:501-511.
2. Schmutzler C, Koehrle J 2000 Innovative strategies for the treatment of thyroid cancer. Eur J Endocrinol 143:15-24.
3. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648.
4. Goretzki PE, Simon D, Frilling A, Witte J, Reiners C, Grussendorf M, Horster FA, Roher HD 1993 Surgical reintervention for differentiated thyroid cancer. Br J Surg 80:1009-1012.
5. Filetti S, Bidart J, Arturi F, Caillou B, Russo D, Schlumberger M 1999 Sodium/iodide symporter: A key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 141:443-457.
6. Brabant G, Maenhaut C, Kohrle J, Scheumann G, Dralle H, Hoang-Vu C, Hesch RD, von zur Muhlen A, Vassart G, Dumont JE 1991 Human thyrotropin receptor gene: Expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation. Mol Cell Endocrinol 82:R7-12.
7. Haugen BR 1999 Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 16:34-41.
8. Kim JH, Leeper RD 1983 Combination adriamycin and radiation therapy for locally advanced carcinoma of the thyroid gland. Int J Radiat Oncol Biol Phys 9:565-567.
9. Kim JH, Leeper RD 1987 Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 60:2372-2375.
10. Orlandi F, Caraci P, Mussa A, Saggiorato E, Pancani G, Angeli A 2001 Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer 8:135-147.
11. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Tagliaferri P, Lupoli G 2001 Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 91:1797-1808.
12. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H 1998 Tumor selective delivery of 5-Fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091-1097.
13. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H 1998 Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58:685-690.
14. Nishimura G, Terada I, Kobayashi T, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Kayahara M, Shimizu K, Ohta T, Miwa K 2002 Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep 9:479-482.
15. Patel A, Pluim T, Helms A, Bauer A, Tuttle RM, Francis GL 2004 Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults. Cancer Chemother Pharmacol 53:409-414.
16. Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D, Morrow M 2002 American Joint Committee on Cancer-Cancer Staging Manual. Springer-Verlag, New York.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG 2000 New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216.
18. Gottlieb JA, Hill CS, Jr. 1974 Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 290:193-197.
19. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R 1985 A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155-2160.
20. Ahuja S, Ernst H 1987 Chemotherapy of thyroid carcinoma. J Endocrinol Invest 10:303-310.
21. Scherubl H, Raue F, Ziegler R 1990 Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 116:21-23.
22. De Besi P, Busnardo B, Toso S, Girelli ME, Nacamulli D, Simioni N, Casara D, Zorat P, Fiorentino MV 1991 Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 14:475-480.
23. Bukowski RM, Brown L, Weick JK, Groppe CW, Purvis J 1983 Combination chemotherapy of metastatic thyroid cancer. Phase II study. Am J Clin Oncol 6:579-581.
24. Hoskin PJ, Harmer C 1987 Chemotherapy for thyroid cancer. Radiother Oncol 10:187-194.
25. Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B, Parmentier C 1996 Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab 81:2541-254.
26. Zlock DW, Greenspan FS, Clark OH, Higgins CB 1994 Octreotide therapy in advanced thyroid cancer. Thyroid 4:427-431.
27. Sarlis NJ 2001 Metastatic thyroid cancer unresponsive to conventional therapies: Novel management approaches through translational clinical research. Curr Drug Targets Immune Endocr Metabol Disord 1:103-115.
28. Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K, Goretzki PE, Roeher HD 1998 Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 22:569-574.
29. Simon D, Korber C, Krausch M, Segering J, Groth P, Gorges R, Grunwald F, Muller-Gartner HW, Schmutzler C, Kohrle J, Roher HD, Reiners C 2002 Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: Final results of a pilot study. Eur J Nucl Med Mol Imaging 29:775-782.
30. Coelho SM, Corbo R, Buescu A, Carvalho DP, Vaisman M 2004 Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. J Endocrinol Invest 27:334-339.
31. Gruning T, Tiepolt C, Zophel K, Bredow J, Kropp J, Franke WG 2003 Retinoic acid for redifferentiation of thyroid cancer-Does it hold its promise? Eur J Endocrinol 148:395-402.
32. Short SC, Suovuori A, Cook G, Vivian G, Harmer C 2004 A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin Oncol (R Coll Radiol) 16:569-574.
33. Mahler C, Verhelst J, de Longueville M, Harris A 1990 Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol (Oxf) 33:261-269.
34. Modigliani E, Cohen R, Joannidis S, Siame-Mourot C, Guliana JM, Charpentier G, Cassuto D, Bentata Pessayre M, Tabarin A, Roger P, et al. 1992 Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma. Clin Endocrinol (Oxf) 36:183-186.
35. Frank-Raue K, Ziegler R, Raue F 1993 The use of octreotide in the treatment of medullary thyroid carcinoma. Horm Metab Res Suppl 27:44-47.
36. Lupoli G, Cascone E, Arlotta F, Vitale G, Celentano L, Salvatore M, Lombardi G 1996 Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide. Cancer 78:1114-1118.
37. Vitale G, Tagliaferri P, Caraglia M, Rampone E, Ciccarelli A, Bianco AR, Abbruzzese A, Lupoli G 2000 Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 85:983-988.
38. 2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer 85:1828-1842.
39. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L 1995 Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407-1412.
40. Leichman C, Lenz H, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg P 1997 Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15:3223-3229.
41. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F, Sobrero A 1999 Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17:1760-1770.
42. Araki Y, Isomoto H, Shirouzu K 2001 Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer. Kurume Med J 48:93-98.
43. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz H-J, Leichman CG, Leichman L, Diasio RB, Danenberg PV 2000 Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322-1327.
44. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, Sugihara K, Hirayama R 2003 Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 9:786-791.
45. Petty RD, Cassidy J 2004 Novel fluoropyrimidines: Improving the efficacy and tolerability of cytotoxic therapy. Curr Cancer Drug Targets 4:191-204.
46. Eliason JF, Megyeri A 2004 Potential for predicting toxicity and response of fluoropyrimidines in patients. Curr Drug Targets 5:383-388.
47. Hasegawa S, Seike K, Koda K, Takiguchi N, Oda K, Hasegawa R, Miyazaki M 2005 Thymidine phosphorylase expression and efficacy of adjuvant doxifluridine in advanced colorectal cancer patients. Oncol Rep 13:621-626.
48. Terashima M, Fujiwara H, Takagane A, Abe K, Araya M, Irinoda T, Yonezawa H, Nakaya T, Oyama K, Takahashi M, Saito K 2002 Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. Eur J Cancer 38:2375-2381.
49. Ciccolini J, Evrard A, Cuq P 2004 Thymidine phosphorylase and fluoropyrimidines efficacy: A Jekyll and Hyde story. Curr Med Chem Anticancer Agents 4:71-81.
50. Iqbal S, Lenz HJ 2003 Targeted therapy and pharmacogenomic programs. Cancer 97:2076-2082.
51. Cascinu S, Aschele C, Barni S, Debernardis D, Baldo C, Tunesi G, Catalano V, Staccioli MP, Brenna A, Muretto P, Catalane G 1999 Thymidylate synthase protein expression in advanced colon cancer: Correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 5:1996-1999.
52. Aschele C, Debernardis D, Tunesi G, Maley F, Sobrero A 2000 Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 6:4797-4802.